Oncidium foundation published a Survivornet Connect discussion examining whether PSMA-targeted radioligand therapy could deliver greater benefit when introduced earlier
Public source
Publisher name
Public post
Where does radioligand therapy belong in the treatment of high-risk prostate cancer, a topic close to my heart (closer to my prostate)? In this important SurvivorNet Con…
Company
Oncidium foundation
Promote, support and accelerate the development of radiotheranostics for cancer care, worldwide.
- Industry
- Non-profit Organizations
- Location
- Brussels, BE
- Company size
- 51–200 employees
About Oncidium foundation
The Oncidium foundation was created in 2011 to promote the development of nuclear medicine therapy through the dissemination of reliable and complete information for patients. Radiotherapeutics and radiotheranostics represent a new class of drugs that can be used for patient suffering from incurable cancers. The Foundation's priority include promoting the awareness among patients and physicians, investing in research and scholarship, supporting and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice and improving access to patients.
See moreLatest activity
Latest activity from Oncidium foundation
6 signals
Presence & Recognition
Oncidium foundation participated in the Latin American Nuclear Olympiad 2026, which focused entirely on Radiotheranostics.
Partnerships
Oncidium foundation established a partnership with Hackapower Oficial to advance radiotheranostics.
Presence & Recognition
Oncidium foundation hosted the first Virtual Radiotheranostics Summit in collaboration with the MEDICAID CANCER FOUNDATION.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
OncologyTube.com
OncologyTube.com published practice notes detailing PSMA PET gate dosing with six q6-week 7.4 GBq doses with investigator-choice ARPI and ADT, along with radiation, marrow, and renal monitoring counsel.
Research & Knowledge
Nucleus RadioPharma
Nucleus RadioPharma published a new open-access study in the Journal of Nuclear Medicine comparing commercially produced and in-house produced [¹⁷⁷Lu]Lu-PSMA-617 and [¹⁷⁷Lu]Lu-PSMA I&T in 140 propensity-matched mCRPC patients.
Research & Knowledge
CDL Nuclear Technologies
CDL Nuclear Technologies published a recent longitudinal study using F18 FDG-PET/MRI findings that androgen deprivation therapy (ADT) was associated with progressive arterial inflammation in men with prostate cancer.
Research & Knowledge
Alliance Medical UK
Alliance Medical UK highlighted that the major challenge facing PSMA PETCT in prostate cancer has shifted from demonstrating diagnostic value to ensuring equitable access in routine clinical practice.
Research & Knowledge
Friends of Cancer Research